CytomX Therapeutics gets FDA Fast Track for Varseta-M in mCRC
CytomX Therapeutics says the FDA granted Fast Track designation to Varseta-M for relapsed/refractory metastatic colorectal cancer (R/R mCRC).
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.